1. Resistant CML: Understanding the Science to Change Outcomes

2. Program Goal

3. Treating CML With TKIs

4. Where Do 2nd Generation TKIs Fit in Front-line Therapy?

5. Late Toxicities

6. IRIS Trial

7. Progression-Free Survival: Bosutinib

8. BELA Trial

9. Treatment Side Effects

10. Response Monitoring

11. European Leukemia Net Guidelines

12. Frequency of Monitoring Patients

13. Changing Therapy After Intolerance to Imatinib

14. TIDEL-II Study

15. Evaluating Responses

16. BCR-ABL Mutation Testing

17. When to Measure Transcript Levels

18. Evolution of Transcript Level Over Time

19. Is Resistance Futile?

20. Ponatinib Pan BCR-ABL Inhibitor

21. Suppression of Mutant Outgrowth

22. Phase 1 Study of Ponatinib – Duration of MCyR in CP-CML

23. PACE Trial

24. Stop Imatinib (STIM) Study

25. Thank you for participating in this activity.

26. Novel Agents for CML

27. Phase 1 Study: DCC-2036

28. Phase 1a: Oral Hedgehog Inhibitor PF-04449913